Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Keytruda Market In 2029?

The market for Keytruda has expanded swiftly in the past few years. It is anticipated to rise from $21.6 billion in 2024 to $23.8 billion in 2025, with a Compound Annual Growth Rate (CAGR) of 10.2%. This growth during the historical period can be credited to factors such as better patient results, higher usage of immunotherapy, research and development efforts, improved patient adherence, and increased acceptance of Keytruda.

What Growth Rate Is Forecasted for the Keytruda Market by 2029?

In the coming years, the market size for Keytruda is anticipated to witness robust growth, reaching a value of $34.61 billion in 2029 with a compound annual growth rate (CAGR) of 9.8%. Factors contributing to this significant growth during the forecast period include the rise in the number of indications, developing markets, increased occurrence of cancer, escalated healthcare spending, and a surge in the need for precision medicine. The forecast period will also observe trends such as the rising demand for targeted therapies, advancements in immunotherapy and diagnostic technology, a growing need for cancer treatment, and progressive strides in cancer research.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16457&type=smp

Which Key Companies Are Shaping the Future of the Keytruda Market?

Major companies operating in the keytruda market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis AG, AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Biogen Inc., Chugai Pharmaceutical Co. Ltd., BioNTech AG, Organon Co., Ono Pharmaceutical Co. Ltd., Samsung Bioepis Co. Ltd., Fate Therapeutics Inc., Merck Sharp & Dohme Corp., KinBio, Schering-Plough AB, LGM Pharma LLC, Gritstone Bio Inc.

Which Factors Are Driving Demand in the Keytruda Industry?

The escalating incidence of cancer is anticipated to boost the development of the keytruda market in the future. Cancer is a multifaceted collection of diseases marked by abnormal cell growth and proliferation. The incident of cancer is attributed to genetic, lifestyle, environmental, and hormonal elements. Keytruda (pembrolizumab) aids in cancer therapy by primarily utilizing the body’s immune system to combat cancer cells more effectively. It signifies a substantial breakthrough in cancer care, employing the immune system’s power to aim for and strike cancer cells, offering renewed optimism for many patients with advanced or metastasized cancers. For instance, the American Cancer Society, a non-profit cancer advocacy organization based in the US, reported in January 2024 that the number of cancer cases surged to 2,001,140 from 1,958,310 in 2023, indicating a 2.19% growth. Therefore, the escalating incidence of cancer propels the keytruda market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=16457&type=smp

How Is the Keytruda Market Segmented by Several Divisions?

The keytruda market covered in this report is segmented –

1) By Cancer Type: Melanoma, Lung Cancer, Head And Neck Cancer, Hodgkin Lymphoma, Stomach Cancer, Urothelial Carcinoma

2) By Payer Type: Commercial, Medicare, Medicaid

3) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies

Subsegments:

1) By Melanoma: Advanced Or Unresectable Melanoma, Adjuvant Treatment For Melanoma

2) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

3) By Head And Neck Cancer: Squamous Cell Carcinoma Of The Head And Neck (SCCHN), Recurrent Or Metastatic Head And Neck Cancer

4) By Hodgkin Lymphoma: Classical Hodgkin Lymphoma, Relapsed Or Refractory Hodgkin Lymphoma

5) By Stomach Cancer: Advanced Or Metastatic Gastric Cancer, Esophagogastric Junction Cancer

6) By Urothelial Carcinoma: Advanced Or Metastatic Urothelial Carcinoma, Muscle-Invasive Bladder Cancer

What are the Emerging Market Trends Driving the Growth of the Keytruda Industry?

Key players in the Keytruda market, such as Merck, are moving forward with the development of pioneering products like pembrolizumab to broaden the scope of treatment possibilities. Pembrolizumab, a type of medication classified as an immune checkpoint inhibitor, is a monoclonal antibody. It is being sold under the brand name, Keytruda, and functions by specifically targeting and inhibiting a protein known as PD-1 (programmed cell death protein 1) found on T immune cells. In November 2023 for instance, Merck, a US-based firm that produces Keytruda, introduced KEYTRUDA (pembrolizumab) in tandem with fluoropyrimidine- and platinum-infused chemotherapy, approved by the US-based Food and Drug Administration. This combination has proven to elevate overall survival rates and freedom from disease progression, outshining chemotherapy as a singular treatment, showing positive developments in gastric cancer treatment. Clinical trials have further proven the advantages of this combined therapy in terms of enhancing overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) compared to the lone use of chemotherapy.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/keytruda-global-market-report

Which Regions Are Driving Growth in the Keytruda Market?

North America was the largest region in the keytruda market in 2023. The regions covered in the keytruda market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16457

This Report Delivers Insight On:

1. How big is the keytruda market, and how is it changing globally?

2. Who are the major companies in the keytruda market, and how are they performing?

3. What are the key opportunities and risks in the keytruda market right now?

4. Which products or customer segments are growing the most in the keytruda market?

5. What factors are helping or slowing down the growth of the keytruda market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model